CASI Projected Dividend Yield
Ord/CASI Pharmaceuticals Inc (New) ( NASDAQ : CASI )CASI Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world. Co. is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the U.S.. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. 21 YEAR PERFORMANCE RESULTS |
CASI Dividend History Detail CASI Dividend News CASI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |